Search
forLearn
5 / 801 resultslearn DMSO
learn TDM-105795
learn DECAPEPTIDE-28
learn APISCALP™
Research
5 / 28 results
research Basics of Hormonal Contraception
Hormonal contraceptives are effective for teens but require careful consideration of side effects and individual health.
research Outcome Measures in Cutaneous Autoimmune Disease: Dermatomyositis and Lupus Erythematosus
The document concludes that better tools are needed to measure skin disease severity in dermatomyositis and cutaneous lupus erythematosus, and introduces the DSSI and CLASI as reliable instruments.
research A Review of Androgen‐Progestin Regimens for Male Contraception
Hormonal male contraception is effective and could be market-ready, but more research is needed to ensure safety for all ethnic groups.
research THE PEDIATRICIAN AND THE SEXUALLY ACTIVE ADOLESCENT
Pediatricians should advise sexually active teens on safe sex and STD prevention, and discuss contraceptive options and their side effects.
research Management of Clinical Side Effects of DMPA
To improve use of the contraceptive DMPA among adolescents, effectively manage side effects like menstrual changes and weight gain through counseling and guidance.
Community Join
5 / 1000+ resultscommunity The lowest cyproterone dose to stop mpb
community Treating my DUPA via controlling inflammation
The user has DUPA and suspects autoimmune activity as a cause. They have tried various treatments including finasteride, minoxidil, dutasteride, pyrilutamide, estrogel, hydrocortisone, and clobetasol, and are now seeking a long-term immunosuppressant.
community Phase II for Technoderma Therepeutic's TDM-105795 set to begin in April tentatively
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
community Trial for TDM-105795 update from research office
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
community New company created by Dr. Kang-Yell Choi to commercialize PTD-DBM therapy
PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.